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Abstract
The tumor suppressor protein, p53 responds to cellular stress such as DNA damage, 
oncogenic activation and hypoxia by transactivating downstream genes that are respon-
sible for apoptosis, DNA repair, senescence, cell cycle arrest and cell cycle progression. 
However, emerging trends show that p53 also plays multifaceted roles in regulating 
glucose metabolism. It promotes oxidative phosphorylation, suppresses glycolysis at 
multiple points as well as controlling glutamine and lipid metabolism. Current findings 
suggest that p53 actions have potential to influence the Warburg Effect, that is, charac-
teristic of cancer cells. The Warburg phenomenon is characterized by their preference 
for glycolysis to oxidative phosphorylation for ATP generation, irrespective of adequate 
oxygen supply. This is often in concomitance with enhanced glucose uptake and leads 
to increased lactate production and anabolic processes such as lipid synthesis and  
de novo nucleic acid synthesis. The molecular underpinnings of the Warburg Effect are 
still poorly understood. These important differences between cancer and normal cells 
have induced interest in glucose metabolism as a drug target. This chapter focuses on 
the influence p53 exerts on glucose metabolism as well as on the implications of the 
Warburg phenomenon in carcinogenesis and a review of the ever-increasing number of 
p53 regulators.
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1. Introduction
Most normal differentiated cells rely primarily on oxidative phosphorylation and, to a lesser 
extent, on glycolysis for the generation of ATP. Cancer cells prefer glycolysis to oxidative 
phosphorylation for ATP generation from glucose even in the presence of adequate supply 
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of oxygen, a phenomenon that was first described by Otto Warburg in 1927 [1]. This often 
occurs alongside rapacious uptake of glucose and leads to increased lactate production and 
elevation of the pentose phosphate pathway (PPP). In addition to synthesizing nucleotides, 
the PPP generates large amounts of nicotinamide adenine dinucleotide phosphate hydrogen 
(NADPH) conferring anti-oxidant properties to cancer cells and thereby protecting them from 
potential damage by reactive oxygen species [2].
Previously, Hannan and Weinberg identified and reviewed six hallmarks of cancer [3]. The 
Warburg effect is now recognized as the seventh [4]. Given the multifaceted interventions 
by p53 in glucose metabolism, it would not be surprising that this potent tumor suppressor 
exerts substantive influence on the Warburg effect. p53 is tightly regulated in normal physiol-
ogy but is activated by post-translational modifications following one or more of several cel-
lular stresses such as DNA damage, oncogenic activation, hypoxia, ribonucleotide depletion 
and telomere erosion [5]. p53 activation triggers a suit of signaling cascades by either p53 
transcription-dependent or -independent pathways. In normal cellular conditions, wild type 
p53 is kept under tight regulation mainly by the Mouse double minute (MDM2) which uses 
its E3 ligase activity to ubiquitinate p53 thereby tagging it for proteasomal degradation [6]. 
This stringent control of p53 is consistent with its well-known role in maintaining genomic 
and cellular integrity.
Over the years, many negative regulators of p53 have been identified further complicating the 
functional map of this ubiquitous tumor suppressor. Given recent findings about the impor-
tance of p53 in glucose metabolism, it is necessary to reassess the extent to which metabolic 
reprogramming and absence of functional p53 contributes to carcinogenesis. p53 regulates 
glucose metabolism at multiple points effecting outcomes such as repression of glucose trans-
port, inhibition of glycolysis, positive influence on oxidative phosphorylation and control of 
glutamine and lipid metabolism (Figure 1).
Figure 1. p53, although well-known for inducing apoptosis and cell cycle arrest for tumor suppression, it also employs 
several strategies via metabolic pathways for tumor suppression such as blocking glucose transport, inhibiting 
glycolysis, boosting oxidative phosphorylation, promoting glutamine metabolism, enhancing fatty acid oxidation in low 
glucose conditions and inhibiting lipid synthesis. p53 also promotes nucleotide metabolism. The asterisks indicate that 
the enhancement of fatty acid oxidation by p53 is only in conditions of low glucose (1 mM).
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2. The impact of p53 on glucose metabolism
p53 is mutated in more that 50% of all cancers. Moreover, the development of many anti-can-
cer drugs often depends on the status of the p53 gene in the targeted cancer. Recent findings 
show p53 intervenes in the glucose metabolic pathways at multiple points (Figure 2). Overall, 
p53 inhibits glycolysis and promotes oxidative phosphorylation (Figure 2).
2.1. Control of glucose transport
The first rate-limiting step for glucose metabolism is the uptake of glucose which is facilitated 
by glucose transporters at the cell membrane such as GLUT1-4. These receptors are often over-
expressed in many cancers. Hence, carcinogenesis is associated with increased glucose uptake 
and glycolysis. This is mediated by glucose transporters. Consequently, glucose uptake is 
used for diagnosis and monitoring of cancer and metastasis in patients using positron emis-
sion tomography (PET) imaging technique that is based on consumption of the glucose analog 
2-(18F)-fuoro-2-deoxy-D-glucose by cells [7, 8]. Under physiological conditions, p53 monitors 
glucose uptake by suppressing the expression of transporters such as GLUT1 and GLUT4 by 
directly binding to the p53 response elements in their promoters [9]. This indicates that p53 
can inhibit energy metabolism by obstructing cellular glucose uptake. p53 can also indirectly 
repress glucose intake via Glut3 by activating the IKK-NFκB pathway. In p53-deficient cells, 
there is an increase in aerobic glycolysis and upregulation of Glut3 accompanied by increased 
Figure 2. p53 inhibits glucose influx by directly repressing the expression of GLUT1 and GLUT4. However, p53 indirectly 
inhibits GLUT3 expression by repressing NFkB transcriptional activity on GLUT3 through inhibition of I kappa B kinase 
(IKK). p53 also represses glycolysis by inhibiting phosphoglycerate mutase expression and activating TP53-induced 
glycolysis and apoptosis regulator (TIGAR) which suppresses glycolysis. OXPHOS can be promoted by p53 through the 
activation of SCO2 at Complex IV. p53 can inhibit PDK which can phosphorylate pyruvate dehydrogenase and prevent 
its catalysis of pyruvate to acetyl-CoA. INSERT: p53 inhibits glycolysis and boosts OXPHOS.
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activity of the IKK-NFκB axis. This accelerated glycolysis can be suppressed by elimination of 
the p65/NFκB complex and restored by expression of Glut3 [10]. These observations indicate 
that glycolysis may also influence the IKK-NFκB pathway which is activated by inflammatory 
molecules such as cytokines, reactive oxygen species (ROS) and by radiation.
2.2. Suppression of glycolytic pathway by p53
The p53 target gene, TP53-induced glycolysis and apoptosis regulator (TIGAR) intervenes at the 
third step of glycolysis by dephosphorylating fructose,2,6-phosphate, which is a potent stim-
ulator of glycolysis and an inhibitor of gluconeogenesis, to fructose-6-phosphate (Figure 2). 
p53 also modulates the transcription of TIGAR by binding to p53 response elements in the 
promoter region, thereby controlling the levels of fructose,2,6-phosphate. Hence, p53 can 
block glycolysis by activating TIGAR and lowering the levels of fructose-2,6-biphosphate, 
which is a potent activator of phosphofructokinase-1 that is responsible for converting fruc-
tose-6-phosphate to fructose1,6-bisphosphate. Thus, the activation of TIGAR inhibits gly-
colysis and shunts glucose breakdown through the pentose phosphate pathway [11, 12]. It 
is expected then that loss of p53, which occurs in most cancers, would lead to increase in 
fructose,2,6-phosphate and in glycolysis.
Phosphoglycerate mutase (PGM) is a glycolytic isomerase that catalyzes step 8 of glycolysis, 
converting 3-phosphoglycerate to 2-phosphoglycerate and is repressed by wild type p53 in 
mouse embryonic fibroblasts (MEFs). When expression of PGM is elevated, high glycolytic 
flux is observed and the MEFs are immortalized [13]. Furthermore, PGM is upregulated in p53 
null cells. Evidence shows that PGM controls a critical step in glycolysis where the process is 
shunted to the pentose phosphate pathway (PPP) because when it is depleted by shRNA or by 
an small molecule inhibitor, glycolysis is reduced, PPP flux occurs and cell proliferation and 
tumor growth are inhibited [14, 15].
p53 also represses the transcription of pyruvate dehydrogenase kinase 2 (PDK2) thereby 
inhibiting the conversion of pyruvate to acetyl coA and production of lactic acid in breast car-
cinoma cells (MCF7). This underlines that p53 plays a pivotal role in establishing the Warburg 
Effect whereby pyruvate is converted to lactate even in abundant oxygen conditions [16].
Taken together, the above observations show that under normal physiological conditions, p53 
inhibits glucose metabolism while boosting oxidative phosphorylation (OXPHOS). When p53 
is dysfunctional, as it happens in many cancers, this scenario is reversed a situation that is 
consonant with the Warburg Effect.
2.3. p53 influence on lactate metabolism
Pyruvate, which is the product of glycolysis, is the key branch point at which glucose metabo-
lism can go either to lactate production or to the tricarboxylic acid cycle (TCA). The conversion 
of pyruvate to acetyl-Coenzyme A, which enters the TCA, is catalyzed by pyruvate dehydro-
genase complex (PDC). The enzyme pyruvate dehydrogenase kinase isoenzyme-2 (Pdk2), 
which inactivates acetyl-CoA production by phosphorylating the PDC, is negatively regu-
lated by p53 [16]. Lactate is no longer regarded as merely a waste product of glycolysis, but 
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also as a significant regulator of carcinogenesis and metastasis, acting as fuel and as a signal 
molecule that promotes angiogenesis via VEGF [17, 18]. Moreover, the conversion of pyruvate 
to lactate is enhanced in neoplastic cells and utilizes NADH and H+ to yield the NAD+ that 
is used in the conversion of glyceraldehyde-3-phosphate to 1,3-biphosphoglycerate which 
refuels glycolysis. Tumor cells generally export the excessive lactate along with protons via 
monocarboxylate transporters (MCT) instead of utilizing it as a nutrient. This leads to an acid-
ification of the tumor microenvironment and contributes to immune evasion. Lactate export 
establishes low pH and induces the production of pro-inflammatory cytokines by inflamma-
tory cells in the tumor microenvironment. The cytokine expression is facilitated by “lactate 
response elements” in the promoters of the genes encoding these cytokines [19]. Wild type 
p53 directly interacts with the promoter of the MCT1 gene and represses it. Consequently, 
cancer cells that are deficient in p53 have elevated levels of MCT1 and proliferate. This phe-
notype also enables them to modulate import or export of lactic acid depending upon glucose 
availability [20]. Various isoforms of MCT including MCT1, MCT4 and chaperone CD147, are 
highly increased in renal cell carcinomas and also indicate poor prognosis. Furthermore, MCT 
has been suggested as a potential target for anti-cancer drugs, whose strategy is to reverse the 
Warburg Effect [21].
Lactate dehydrogenase-A (LDH-A), an important prognostic marker in several tumors, cata-
lyzes the conversion of pyruvate to lactate in anaerobic conditions with concomitant oxida-
tion of reduced nicotinamide adenine dinucleotide (NADH) to NAD+. LDH-A expression is 
upregulated by several oncogenes, including c-Myc [22], Her2/Neu through heat shock fac-
tor 1 [23]) and hypoxia-inducible factor 1α (HIF-1α) [24] all of which are influenced by p53. 
p53 is also known to regulate lactate metabolism by indirectly suppressing LDH-A activity 
through miR-34 because p53 transactivates and upregulates them via p53 response elements 
on their promoters. In turn, miR-34a suppresses LDH-A activity in vitro and in vivo and has 
been shown to possess tumor suppressor functions [25–29]. Furthermore, miR-34a activation 
leads to apoptosis and to upregulation of several genes that are involved in cell cycle regula-
tion, DNA repair and angiogenesis. These findings show that miR-34 is part of the p53 tumor 
suppression network.
2.4. p53 enhances oxidative phosphorylation (OXPHOS)
Oxidative phosphorylation is a metabolic process that occurs in the mitochondria to generate 
larger amounts of ATP from glucose as compared to glycolysis. It involves sequential trans-
fer of electrons (electron transport chain (ETC)) facilitated by a series of enzymes located in 
the inner mitochondrial membrane thereby generating energy that is used to pump protons 
across the membrane creating an electrochemical gradient. This gradient drives the adenosine 
5′-triphosphate (ATP) synthase to “almost mechanically” produce ATP by attaching a phos-
phate to ADP. By this method, the cell is able to produce 36 ATP molecules from a glucose 
molecule compared to 2 ATPs produced by glycolysis [30].
p53 displays multifaceted roles in the regulation of energy metabolism via the mitochon-
dria. It assists in the repair or degradation of unhealthy or worn out mitochondria by induc-
ing the expression of mitochondria-eating (mitophagic) protein (MIEAP) through binding to 
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the MIEAP promoter in response to mitochondrial damage, thereby facilitating good mito-
chondrial quality [31]. p53 is also involved in preserving mitochondrial genetic integrity by 
interacting with mtDNA polymerase gamma (mtDNA polymerase γ) thus improving DNA 
replication and enhancing the mitochondria to respond appropriately to DNA-damaging 
insults. Loss of p53 increases mitochondrial susceptibility to mutations, a phenotype that is 
rescued by wild type p53 [32]. This presents another example of p53 subcellular localization 
and function outside the nucleus. Mitochondrial diseases are characterized by energy deple-
tion probably due to defects in OXPHOS since the primary function of mitochondria is to 
support aerobic respiration [33]. It is thus relevant to review the role of p53 in maintaining 
mtDNA integrity and influence in aerobic glucose metabolism.
The mitochondrion is also the key regulator of apoptosis and by extension, critical in cell cycle 
control and in development of tumors. p53 promotes oxidative phosphorylation by activat-
ing synthesis of cytochrome c oxidase 2 (SCO2) gene enzyme in complex IV of the electron 
transport chain. It transactivates SCO2 by direct DNA binding to the p53 response element 
at the SCO2 promoter region [34]. SCO2 then regulates cytochrome c oxidase (COX) complex 
or complex IV, which is the last enzyme in the ETC and regulates the major site of oxygen 
utilization in the cell.
Matoba et al. showed that even though the total amount of ATP produced by p53−/−, p53−/+ and 
p53+/+ HCT116 cells was roughly the same, the relative proportion of ATP generated by glycol-
ysis showed an inverse proportion to p53 dosage. This suggests that the Warburg Effect does 
not reduce the amount of ATP generated but adjusts the contributions made by glycolysis and 
OXPHOS. Oxidative respiration was, however, rescued in p53−/− cells when the SCO2 protein, 
which is downstream effector in OXPHOS, was expressed. This shows that the decreased 
OXPHOS was mediated in part by decreased levels of SCO2. Furthermore, SCO2+/− knock-
out cells showed the same metabolic profiles and proliferation rate as p53−/− cells [34, 35]. 
In contrast to glycolysis where p53 plays an inhibitory role, it has a positive effect on OXPHOS 
(Figure 2 (insert)). This is consistent with p53 being a driver of the Warburg Effect because 
when it is mutated one expects that OXPHOS would be downregulated and glycolysis upreg-
ulated which is the glycolytic phenotype seen in cancer. However, it appears that this pheno-
type can occur in the background of wild type p53 suggesting that there are other factors that 
are crucial for the establishment of the Warburg Effect.
The Apoptosis-inducing factor (AIF) is a mitochondrial protein, encoded by nuclear DNA. It 
induces apoptosis when apoptotic stimuli cause it to be translocated to the nucleus where, 
together with cyclophilin, it executes the final events of apoptosis, nuclear chromatin conden-
sation and large scale DNA fragmentation [36]. In the mitochondria, AIF maintains structural 
integrity especially of the cristae. Consequently, disruption of mitochondrial location of AIF 
disturbs oxidative phosphorylation [37]. AIF has an important role in the assembly and func-
tion of Complex I of the electron transport chain, as demonstrated in isolated cardiac mito-
chondria obtained from Harlequin and wild type mice [38]. AIF is also a direct transcriptional 
target of p53 and possesses p53 response elements in its promoter, although only basal levels 
of p53 are required with higher levels having no impact on AIF dynamics. The induction of 
AIF expression by p53 is therefore important in supporting cellular OXPHOS activity. AIF and 
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TIGAR, which are both upregulated by p53, are important examples of genes that regulate 
both apoptosis and metabolism; showing the diverse approaches of p53 in tumor suppression.
2.5. The role of p53 in glutamine metabolism
Glutamine is a non-essential amino acid that can be synthesized from glucose. When com-
pared to glucose, it is a less celebrated source of energy and biosynthetic molecules. It pro-
vides nitrogen for the synthesis of nitrogenous bases and amino acids. Glutamine metabolism 
also generates reduced NADP which lowers anti-oxidant stress and is required for fatty acid 
synthesis. Glutaminases catalyze the deamination of glutamine to glutamate, which is further 
processed to generate α-ketoglutarate (an important metabolite in the TCA cycle) thereby 
boosting OXPHOS. α-Ketoglutarate can also be converted to citrate, which may be exported 
out of the cell for amino acid and synthesis of lipid which are important in proliferating cells. 
Glutamine can also be metabolized to pyruvate, which is further processed to lactate. Two 
types of glutaminase, encoded by two separate genes have been discovered: the kidney type 
glutaminase (GLS1) predominantly expressed in the kidneys and the liver type GLS2 which 
is highly expressed in hepatocytes. GLS1 and GLS2 show contrasting roles in carcinogenesis 
and seem to depend on the origin of the tumor. For example, increased glutamine metabolism, 
corresponding to enhanced expression of GLS1 is characteristic of several cancers including 
colorectal and hepatocellular carcinomas [39, 40] while downregulation in GLS2 is associated 
with hepatocellular cancers [41]. Moreover, GLS1 is an attractive target in glutamine-addicted 
tumors. A recent study showed that the small molecule glutaminase inhibitor, CB-839 exhibits 
anti-proliferative effects in triple negative breast cancer cells [42].
Studies by Suzuki et al. and Hu et al. showed that phosphate-activated glutaminase 2 (GLS2) 
is a p53 inducible gene which enhances OXPHOS and increases ATP production as well as 
glutathione levels [41, 43]. Two mechanisms by which GLS2 may inhibit cancer progres-
sion have been elucidated. Firstly, GLS2 represses the phosphatidylinositol 3 kinase/protein 
kinase B (PI3K/PkB) pathway which is upregulated in several tumors [44, 45]. It is noteworthy 
that the PI3K/PkB pathway, in addition to promoting cell proliferation, also boosts glycolysis 
[46]. Secondly, GLS2 represses the GTPase protein, Rac1, which is known to promote inva-
sion, migration and metastasis in cancer cells through the regulation of actin dynamics [45]. 
Moreover, glutamine metabolism is another metabolic signature in carcinogenesis, because 
cancers consume large amounts of glutamine in culture and in vivo. In fact, the term “gluta-
mine-addicted tumors” has been coined for such tumors and may be exploited for anti-cancer 
drug discovery. In addition to amino acid biosynthesis, glutamine serves other cellular func-
tions including helping to maintain good mitochondrial membrane potential and integrity 
and modulating P13K-Akt and EGFR signaling which, in turn, stimulate glycolysis [47].
2.6. p53 reduces oxidative stress
p53 generally enhances OXPHOS activities which may inadvertently generate mitochondrial 
reactive oxygen species (ROS). ROS are key signaling molecules in cell proliferation in both 
cancer and in normal cells. Nevertheless, ROS can lead to damage of membranes, proteins 
and DNA, with DNA damage leading to genomic instability [48].
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In addition to the incidental ROS production, p53 actively generates ROS by activating a net-
work of genes that are directly involved in ROS generation. Consequently, a deficiency in p53 
will results in oxidation of DNA and genomic instability which can be avoided by treatment 
with anti-oxidants [49]. To circumvent this problem, p53 upregulates handful of genes that 
protect a cell from oxidative stress. For example, GLS2-mediated glutathione synthesis as a 
consequence of glutaminolysis is known to protect cells from oxidative stress. A glutathione 
molecule gets rid of ROS by accepting an electron from it, and is oxidized to glutathione 
disulfide. Glutathione reductase is an enzyme that uses NADPH to catalyze the conversion of 
glutathione disulfide back to its reduced form, glutathione. The Tp53-induced glycolysis and 
apoptosis regulator (TIGAR) was shown to enhance the generation of reduced glutathione 
thereby protecting cells from ROS-mediated apoptosis [11]. p53 also transactivates glutathi-
one peroxidase 1 (GPX1) [50] and aldehyde dehydrogenase 4 (ALDH4) [51], which are also 
important in reducing oxidative stress.
2.7. p53 influence in lipid metabolism
More than 90% of lipids required by tumors are produced by de novo synthesis. Precursors 
of these critical elements of the plasma membrane are generated by glucose metabolism. 
Furthermore, fatty acids play essential roles in signal transduction, phospholipid formation 
for the synthesis of membranes and energy storage required by rapidly proliferating cells. 
Metabolism of fatty acids in mitochondria through β-oxidation generates large amounts of 
energy. The availability of fatty acids has been shown to influence cell proliferation, and their 
metabolism is deregulated in several cancers. While increased fatty acid oxidation (FAO) may 
play a role in suppressing tumor growth, increased fatty acid synthesis which correlates with 
overexpression of fatty acid synthase and ATP citrate lyase connotes poor tumor prognosis 
[52–54]. It has been demonstrated that p53 influences cellular fatty acid metabolism. A family 
of transcription factors known as sterol regulatory element-binding proteins (SREBPs) tran-
scriptionally regulates lipogenesis. p53 inhibits SREBP1c which is known to transactivate genes 
that promote fatty acid synthesis including FASN and ACLY [55]. However, p53 may promote 
FAO during glucose starvation by transactivating Lpin1a Mg2+-dependent phosphatidate 
phosphatase enzyme that catalyzes the conversion of phosphatidate (PA) to diacylglycerol. 
Figure 3. p53 primarily inhibits lipid synthesis by inhibiting SREBP1c which is known to transactivate ACLY and FASN 
which catalyze fatty acid synthesis. p53 also transactivates Lpin1 during glucose deprivation, thereby increasing fatty 
acid oxidation for the generation of ATP.
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It is a bi-functional protein that represses and promotes FAO in mouse myoblasts at normal 
(25 Mm) or low (1 Mm) glucose concentrations in a ROS and ATM-dependent manner [56]. 
p53-mediated upregulation of Lpin1 represents a pro-survival function and confers the abil-
ity to cope with stress such as nutrient (glucose) deprivation. Inhibiting fatty acid synthesis 
by targeting the enzymes and transcription factors that promote lipogenesis is an attractive 
strategy in the development of anti-cancer drugs. For example, RNAi-mediated knockdown 
of FASN in prostate carcinoma resulted in decreased levels of triglycerides and phospholip-
ids and a reduction in cell volume as well as cell-to-cell contacts [57]. Furthermore, deplet-
ing the lipogenic transcription factor SREBP1 using shRNA slowed down lipogenesis and 
reduced endometrial tumor growth [58] (Figure 3).
3. Gain-of-function mutations in p53 and carcinogenesis
Many cancers are associated with loss of p53 function often due to mutations to its DNA-
binding domain. More than half of all human tumors contain mutations or deletions of p53. 
The remainder involves mutations in genes that regulate the p53 pathway. The hotspots, 
comprising about 95% of p53 mutations, are missense mutations in the DNA-binding 
domain. Many of these mutations have been shown to severely restrict p53 function [59]. 
Since p53 is a major tumor suppressor offering protection against cancers, its loss of func-
tion results in vulnerability to cancer-causing agents and aberrant growth of affected cells. 
Over the years, it has emerged that there is a subset of p53 mutations whereby p53 acquires 
new properties such as enhanced growth capacity, antiapoptotic activity, invasiveness and 
anti-cancer drug resistance [60]. These gain-of-function (GOF) mutants have thus become a 
subject of intense research.
The p53 GOF mutations were formally explored, for the first time, in cell lines whereby muta-
tions introduced in a null p53 background were found to cause increased tumorigenicity in 
nude mice and enhanced growth support to the cells in soft agar [61]. Critically, these experi-
ments showed that these mutants, in contrast to wild type p53, were able to transform p53 
null cells and endow them with new properties. This property was responsible for the erro-
neous identification of p53 as an oncogene when it was discovered since wild type p53 does 
not have these characteristics [62]. Later, it was shown that one mechanism by which some 
of these mutations may affect carcinogenesis is by inhibiting the adenosine monophosphate 
(AMP)-activated protein kinase (AMPK) a key energy sensor that is activated in conditions 
of stress [63]. In this study, the GOF mutant p53 inhibited AMPK signaling in head and neck 
cancers. It was shown that it preferentially binds to the AMPKα subunit thereby increasing 
anabolic metabolism, causing metabolic reprogramming and inducing an invasive growth 
phenotype. Normally, p53 and AMPK act via a positive feedback mechanism whereby 
AMPK establishes a metabolic checkpoint by post-transcriptionally stabilizing p53. In turn, 
p53 activates AMPK transcriptionally thereby activating the gene that encodes the β subunit 
of AMPK [64] and sestrin [65, 66]. Among others, key pathways that are upregulated by 
p53 GOF mutations include the epidermal growth factor receptor (EGFR) [67], the vascular 
endothelial growth factor expression (VEGFR) [68] and insulin-like growth factor I receptor 
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(IGF-1R) [69] pathways. These are mostly mitogenic growth factor pathways that play crit-
ical roles in carcinogenesis, further underlining the clinical significance of GOF mutants. 
Many p53 mutations occur in the DNA-binding domain (DBD) and alter the proteins tertiary 
structure affecting its transcriptional activity and resulting in loss of function. Known GOF 
mutants include P151S, R175H, G245C and R282W.
There is also evidence showing that the GOF mutants can aggregate with wild type p53 in 
some cancers and that suppression of this aggregation restores the wild type p53 activity, 
including that of its paralogs p63 and p73. This introduces a novel mechanism of carcinogen-
esis involving aggregation [70]. The fact that certain cancers with p53 GOF are more aggres-
sive than others with poor prognosis underlines their significance. Furthermore, some GOFs 
confer resistance to anti-cancer treatments.
4. p53 negative regulators
p53 is involved in numerous biological activities and new functions continue to be discov-
ered. It is thus not surprising that the list of p53 regulators also continues to grow. Table 1 
shows known negative regulators of p53. It would not be surprising that the list of negative 
regulators will continue to grow in the near future.
The half-life of p53 is limited only to a few minutes in unstressed cells and its tight regulation 
in most cells is known to be controlled by Murine double minute 2 (MDM2), its prototypical 
negative regulator [77]. However, following DNA damage and other cellular stresses, p53 
rapidly stabilizes by post-translational modifications such as phosphorylation and acetyla-
tion and the half-life extends to hours causing it to accumulate in the cell [5, 78]. The diversity 
in p53 negative regulators is still not fully understood but some examples show that they 
can be targets for anti-cancer drug discovery as they provide the mechanism for reactivating 
p53. This strategy, however, also comes with a critical caveat as it has been shown that in 
the absence of Mdm2, p53 can be spontaneously activated [79]. The main negative regula-
tors of p53 are E3 ubiquitin ligases which tag p53 for proteasomal degradation and include 
MDM2, Pirh2 and COP1. These regulators generally bind to the DNA-binding domain of p53, 
preventing it from transactivating its target genes. Jun-N (amino)-terminal kinase (JNK) also 
P53 negative regulators Mode of action with p53 in brief Reference
MDM2 E-3 ligase activity. Forms autoregulatory feedback loop with p53 [6]
Pihr2 E-3 ligase activity. Forms autoregulatory feedback loop with p53 [71]
COP1 E-3 ligase activity. Forms autoregulatory feedback loop with p53 [72]
Jun-N (amino)-terminal kinase 
(JNK) JNK
Binds to and negatively regulates p53 at G0/G1 and S/G2M cell 
cycle phases
[73, 74]
RBBP6 Binds p53 and E3 ligase activity. Shown to enhance MDM2-
mediated ubiquitination.
[75, 76]
Table 1. p53 negative regulators.
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influences p53 ubiquitination and stability probably by acting as an adaptor in the formation 
of the E3 ubiquitin/ligase complex [73]. There is evidence showing that p53 negative regula-
tors can interact with each other independently of op53 and synergistically inhibit it [80].
4.1. Murine double minute 2 (MDM2)
MDM2 is an E3 ubiquitin ligase first discovered in mice. It is the prototypical negative regulator 
of p53 and an oncogene. It is a p53-inducible gene that binds to the 53 transactivation domain 
and regulates p53-mediated gene transcription. Using the E3 ligase activity, MDM2 ubiquiti-
nates p53 and tags it for proteasomal degradation. It also transactivates p53 thereby forming an 
autoregulatory feedback loop [6, 81, 82]. The role of Mdm2 in glucose metabolism in not clearly 
understood but a Mdm2-p53-pyruvate signaling axis has been demonstrated to be activated in 
a diabetic situation where it links mitochondrial respiration to glucose homeostasis [83].
4.2. Pirh2
The p53-inducible gene that encodes a RING-H2 (Pirh2) protein interacts with p53 directly and 
catalyzes its ubiquitination through an intrinsic E3 ubiquitin ligase activity targeting it to protea-
somal degradation. p53 also transactivates Pirh2 providing an autoregulatory feedback loop sim-
ilar to Mdm2-p53 interaction [71]. Pirh2 has been shown to have an impact on lung tumorigenesis 
as increased expression corresponds to reduced levels of p53 and increased cell proliferation [84]. 
To our knowledge, the involvement of Pirh2 in glucose metabolism has not been reported.
4.3. Constitutively photomorphogenic 1 (COP1)
COP1 is a plant protein involved in photomorphogenesis. In Arabidopsis seedlings, for exam-
ple, COP1 controls seedling development by repressing light-mediated gene expression [85]. 
It contains a RING-finger domain for E3 ubiquitin ligase activity. Recently, the molecular and 
functional importance of the human homolog of COP1 was characterized in human bone 
osteosarcoma (U2-OS) cells. Its molecular functions include p53-dependent activities and 
ubiquitination because it is encoded by p53-inducible gene and has E3 ubiquitin ligase activ-
ity. Hence, p53 transactivates COP1 which in turn targets p53 for degradation again forming 
an autoregulatory feedback loop that is similar to MDM2 and Pirh2. siRNA-mediated knock-
down of COP1 stabilizes p53 and causes cells to accumulate in the G1 cell cycle arrest [72].
4.4. The retinoblastoma binding protein 6 (RBBP6)
The longest RBBP6 isoform is 250 kDa protein. All RBBP6 family proteins contain the 
N-terminal Domain With No Name (DWNN). The shortest is isoform 3 which is essentially 
the DWNN. The long isoforms also possess a RING-finger with E3 ligase activity alongside an 
assortment of other domains and motifs. It is a member of a small class of cell cycle regulators 
that binds both p53 and pRb [86]. It is a negative regulator of p53 and has been shown to have 
properties that promote cell proliferation. It is known to act as a scaffold protein associated 
with nuclear matrix and telomeres of chromosomes suggesting an ability to control cellular 
functions to do with cell division and replication [87]. In the mouse model, it was demon-
strated that RBBP6 enhances ubiquitination catalyzed by MDM2. It was, however, shown 
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that the phenotype exhibited by rbbp6−/− mutants was more severe than the mdm2−/− phenotype 
[75, 76]. Although the rbbp6−/− phenotype is strikingly similar to that of mdm2−/−, these results indi-
cate that RBBP6 also possesses roles that are independent of Mdm2. There are many instances 
which show a close association of RBBP6 with carcinogenesis making it an attractive candidate 
for drug targeting. For example, overexpression of RBBP6 alone or in combination with mutant 
p53 is associated with poor prognosis in patients with colorectal cancer. Moreover, its isoforms 
are differentially expressed in many cancers [76, 88]. Interest in RBBP6 and glucose metabo-
lism has been activated by an observation that, in normal cells, the various isoforms including 
isoform 3 which comprises the ubiquitin-like DWNN, become differentially regulated when 
OXPHOS is boosted in cell culture but in cancer cells only the long isoform is expressed [89]. 
This raises questions about its involvement in regulating mitochondrial respiration.
4.5. Jun-N (amino)-terminal kinase (JNK)
JNK is a stress activated kinase that was shown to regulate p53 levels in unstressed cells. It 
is a p53 inducible gene which facilitates p53 ubiquitination tagging it for proteasomal degra-
dation p53 has a JNK binding site which when perturbed either by blocking or by mutation 
abrogates p53 ubiquitination. Like Mdm2-p53 complexes, JNK-p53 complexes are found at 
G
0
/G1 and G2/M checkpoints [73].
5. Anti-cancer drug discovery and development targeting glucose 
metabolism
Preferential killing of cancer cells while protecting normal cells is the most desired outcome 
for anti-cancer drug discovery efforts. With this in mind, the Warburg Effect, as a distinct fea-
ture of cancer cells, offers many opportunities for drug discovery and development. Nearly a 
century ago, since the Warburg phenomenon was discovered in cancer cells, it is still unclear 
whether or not it is a cause or consequence of carcinogenesis [1, 90]. Nonetheless, this met-
abolic signature is shared by many cancers, making it an attractive target for preferential 
therapy as it is distinct from most normal cells. Using the Database for Expressed Sequence 
Tags (dbEST), glycolytic genes have been shown to be upregulated in 24 different types of 
cancer; representing more than 70% of all cases [91]. Central to the regulation of glycolysis 
are three transcription factors: p53, c-Myc and HIF-1α [4]. p53 functions primarily as a tumor 
suppressor that regulates the cell cycle and a network of genes with diverse functions related 
to cell proliferation and cell survival, but it also plays a pivotal role in the Warburg effect 
because mutant p53 (mutp35) acquires a gain-of-function phenotype in cultured cells and 
in knock-in mice in a GLUT1-dependent manner. Inhibition of a downstream effector in this 
GLUT1 pathway abolishes this GOF phenotype [92]. c-Myc (an oncogene) and HIF-1α act in 
complex ways to regulate glucose metabolism—sometimes cooperating but at times acting in 
an opposite manner [93]. A dilemma arises because targeting transcription factors is not an 
attractive strategy as it may result in non-specific outcomes due to the vast array of genes that 
they transactivate.
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Extensive research efforts are underway worldwide to find strategies by which p53 is targeted for 
cancer therapy. In many cases, small molecules are designed to reactivate p53 [5]. The intriguing 
situation is that, the Warburg effect, one of the hallmarks of cancer, can occur in the presence of 
wild type p53. For example, non-small cell lung cancer cell lines A549 (wild type p53) and H1299 
(mutant p53), both exhibit the Warburg effect [94]. Yet it has been shown that perturbation of 
functional p53 is sufficient to induce the Warburg effect in some cells because a mutant form of 
p53 (mutp53) acquired this ability [92]. Thus, drug development based on the Warburg Effect 
should be conducted with some consideration of the p53 status.
In the present study, we update progress made with some drugs and extend the list of drugs 
that are considered as anti-cancer candidates based on glucose metabolism. Studies show 
that cancer cells are more sensitive to inhibitors of glycolysis such as 3-bromopyruvate, oxa-
mate and 2-deoxy-D-glucose in hypoxic tumor microenvironments [95–97]. Several inhibi-
tors of glycolysis that target the Warburg effect as a therapeutic strategy in cancer have been 
reviewed elsewhere [98, 99]. Here, the drugs are divided into categories for convenience:
i. Drugs targeting glucose transport
ii. Drugs targeting glycolysis
iii. Drugs targeting OXPHOS
5.1. Targeting glucose transporters
Enhanced glucose intake is characteristic of several tumors, given their high glycolytic rates, 
and is facilitated by glucose transporters which are often overexpressed [100]. It has been 
shown that depletion of Glut1 transporters by shRNA knockdown and blocking the receptor 
with an anti-Glut1 antibody re-sensitizes cisplatin-resistant cancer cell line [101]. Similarly, a 
Glut1 inhibitor was used to counter 5-fluorouracil (5-Fu) resistant colon cancer [102]. Targeting 
the glucose transporter GLUT1 with a GLUT1-specific inhibitor, WZB117, has been shown to 
inhibit self-renewal and tumor initiation in ovarian, glioblastoma and pancreatic stem cells 
[103]. Another drug, STF1 which selectively inhibits GLUT1, preferentially killed melanoma 
cells and synergistically enhanced cell death induced by anti-cancer drugs melphalan, doxo-
rubicin and bortezomib [104]. It has been demonstrated that expression of the GLUIT1 recep-
tor is absent in sarcomas, lymphomas, melanomas and hepatoblastomas and variable in other 
cancers [105]. This indicates that this drug strategy would require more specific inhibitors to 
target the remaining glucose transporters to manage diverse cancers.
Indirectly, ritonavir, an HIV protease inhibitor, exhibits an off-target effect on GLUT4 and 
has been shown to inhibit GLUT4-mediated glucose transport and to induce apoptosis in 
multiple myeloma cells [100]. Although, we have not found drugs targeting GLUT3 recep-
tors, it appears that inhibition of glucose transport is a feasible strategy for anti-cancer 
drug development. Imatinib mesylate is essentially a tyrosine kinase inhibitor targeting 
Bcr-Abl tyrosine kinase but also has an ability to antagonize the translocation of GLUT2 
receptors to the plasma membrane thereby reducing glucose uptake leading to cancer cell 
death [106].
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5.2. Drugs targeting glycolysis
5.2.1. Lonidamine and 3-bromopyruvate
Following glucose uptake into the cell, the next step is phosphorylation of glucose by hexoki-
nase II. Both lonidamine and 3-bromopyruvate were identified as drugs that repress glycoly-
sis by inhibiting hexokinase II. It was also found to selectively inhibit the electron transport 
chain in the mitochondria of cancer cells indicating that it might affect OXPHOS [107, 108]. 
Furthermore, lonidamine was shown to have an additive rather than a synergistic effect when 
used together with 2-deoxy-D-glucose (2-DG) [109]. Thus far, the lonidamine mechanism of 
action is elusive and after many studies, it is still not clear.
The primary mechanism of action for 3-bromopyruvate (3-BP) is via preferential alkylation of 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). This results in depletion of ATP selec-
tively in cancer cells as they prefer glycolysis for energy production [110]. Systemic delivery 
of microencapsulated 3-BP to pancreatic ductal adenocarcinoma xenograft tumors showed 
promising results with minimal or no tumor progression observed [111]. However, safety 
concerns in the use of 3-BP only were observed in human trials [112].
5.2.2. Pyruvate esters
Interestingly, some pyruvate esters show anti-cancer properties, albeit via different mecha-
nisms. Methyl pyruvate kills lung cancer cell line-A549 cells alone and in combination with 
irinotecan but protects the normal lung fibroblast cell line—MRC5 from irinotecan-induced 
apoptosis probably by inhibiting the p53/p21 axis of the apoptotic pathways during treatment 
and the mitochondrial pathway as well during recovery. Thus, methyl pyruvate has a poten-
tial for use as an adjunctive to chemotherapy [89]. In this case, exogenous pyruvate adds to 
the endogenous thereby boosting OXPHOS and reversing the Warburg Effect. It is reported 
that another pyruvate ester, ethyl pyruvate, preferentially killed leukemia cells by concerted 
mechanisms including cell death by necrosis or apoptosis/ATP depletion and by inhibition 
of glycolytic and para-glycolytic enzymes. Ethyl pyruvate (EP) was also shown to inhibit 
glyoxalase 1 (GLO1), an enzyme that detoxifies the glycolytic bi-product, methylglyoxal. It 
also suppresses glycolytic enzymes, LDH and pyruvate kinase [113]. In another study, ethyl 
pyruvate-reduced mitochondrial apoptosis and protected the murine myeloid cell line 32D 
c13 from radiation. It also increased survival of irradiated C57BL/6NHsd mice. In contrast, the 
inactive analog of EP did not enable such protection [114]. These properties of pyruvate esters 
are interesting as they point to a potential for this molecule as adjunctive in chemotherapy 
and in radiotherapy.
5.2.3.-deoxy-D-glucose (2-DG)
2-DG is a synthetic glucose analog in which a hydrogen atom replaces the C2 hydroxyl group 
such that it cannot be further utilized in the glycolytic pathway. 2-DG competitively inhib-
its glucose uptake, given that it is imported into the cell by glucose transporters (GLUTs). 
Following the import of 2DG into the cell, it becomes phosphorylated by hexokinase to 
2-DG-6-P (2-deoxy-D-glucose-6-phosphate), rather than glucose 6-phosphate. As such, 2-DG 
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competitively inhibits the production of glucose-6-phosphate. 2-DG-6-P cannot be further 
processed, hence it accumulates in the cell and non-competitively inhibits hexokinase and 
competitively inhibits glucose-6-phosphate isomerase [115]. Both glycolysis and OXPHOS are 
partially inhibited, given that the first important steps of glycolysis are inhibited by 2-DG [116]. 
This leads to decreased ATP production which renders cells susceptible to death receptor-
induced apoptosis. 2-DG is also known to block the cell cycle.
5.2.4. TEPP-46
Pyruvate kinase M2 (PKM2) is an alternatively spliced isoform of the key glycolytic enzyme 
PKMI which catalyzes the conversion of phosphoenolpyruvate (PEP) into pyruvate while 
concurrently producing ATP. PKM2 is expressed during embryonic development and in can-
cer cells where is promotes the Warburg Effect, but not in normal adult cells making it an 
attractive target for drug development. Negative regulation of PKM2 in cancer cells results in 
shunting glycolysis to the anabolic pentose phosphate pathway which benefits cancer cells. 
TEPP-46 reactivates pyruvate kinase M2 thereby increasing glycolytic flux and reducing lac-
tate production in cancer cells while deleting intermediates required for entry into the pentose 
phosphate pathway resulting in cancer cell death [117, 118]. It has been demonstrated in vivo 
that reactivation of PKM2 activity and reduction of PPP is a plausible anti-cancer strategy. In 
a xenograft model for non-small lung cancer, TEPP reduced the size of the tumor [118, 119]. 
There is some concern about small molecule inhibitors of PKM2 as they may interfere with 
anabolic activity since they induce constitutive activity. It is noteworthy that PKM2 can act 
as a transcription factor activating transcription of genes which control other aspects of carci-
nogenesis such as Oct-4, hypoxia-inducible factor 1-α (HIF-1α), and β-catenin [120–122]. This 
indicates that small molecule inhibitors of PKM2 may also affect other pathways but this may 
be a positive factor since these pathways are also implicated in carcinogenesis. It also suggests 
that studies of these small molecule inhibitors must also include assessment of the potentially 
affected pathways.
5.2.5. Inhibitors of lactate dehydrogenase-A (LDH-A) and oxamate
LDH-A catalyzes the interconversion of pyruvate, the final product of glycolysis, to lactate 
and nicotinamide adenine dinucleotide (NAD+). The NAD+, thus produced, is reused to fuel 
further glycolysis. Depletion of endogenous LDH-A by RNAi results in death of cancer cells 
regardless of p53 status indicating that it supports their proliferation. However, it was shown 
that the p53 status is required for maintaining the NADH:NAD+ ratio because acetylated 
p53+/+ is important for modulating the NADH:NAD+ ratio. This phenotype is dependent upon 
the NAD+-dependent deacetylase sirtuin 1 (SIRT1). Hence, the anti-cancer activity of small 
molecule drug and redox-sensitive anti-cancer drug EO9 (apaziquone) was enhanced only in 
p53+/+ cells. This indicates that LDH-A is a plausible therapeutic target for anti-cancer drug 
development and that a combinatorial approach that targets LDH-A and the redox status is 
even more effective [123].
EO9 is a bioreductive alkylating agent that causes DNA damage, creating single strand breaks 
and crosslinks [124]. Therefore, it does not target glucose metabolism but is regarded as a 
sensor of the NADH:NAD+ redox status. These findings indicate that inhibitors of LDH-A 
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may have potential as anti-cancer drugs. Indeed, a small molecule inhibitor of LDH-A, FX11 
(3-dihydroxy-6-methyl-7-(phenylmethyl)-4-propylnaphthalene-1-carboxylic acid) causes 
ATP depletion, induces oxidative stress and causes cell death which can be partially reversed 
by anti-oxidants such as N-acetylcysteine [125]. FX11 probably acts by upsetting the Warburg 
Effect because it has been demonstrated that it induces apoptosis in and reduction of patient 
tumor xenographs in a p53-dependnet manner whereby only mutant Tp53 tumors respond 
to the drug [126]. This p53-dependence seen in LDH-A-related responses is interesting as 
it seems to be related to the involvement of p53 in modulating the NADH:NAD+ ratio. The 
molecular mechanism by which p53 would influence this phenotype is unclear and certainly 
requires more investigation. Oxamate is a related drug as it inhibits lactate dehydrogenase 
(LDH) and has been shown to cause death of a breast cancer cell line [127, 128].
5.2.6. Oxythiamine (OT)
The transketolase-like-1-gene (TKTL1) in urothelial and colorectal cancer is associated 
with poor prognosis when overexpressed and was identified as a biomarker. It encodes the 
enzyme transketolase that catalyzes the production of lactate from glucose via the pentose 
phosphate pathway in cancer cells [129]. Oxythiamine (OT) is a transketolase inhibitor that 
arrests growth of cancer cells. This discovery introduced the idea that in general, pentose 
cycle inhibitors provide yet another angle for cancer management [130].
5.3. Drugs targeting OXPHOS or mitochondrial activities
5.3.1. Dichloroacetate
Dichloroacetate (DCA) is an inhibitor of mitochondrial pyruvate dehydrogenase and its 
effect on metabolism is to redirect glucose metabolism from glycolysis to oxidation which 
effectively reverses the Warburg effect. Consequently, it inhibits proliferation and induces 
caspase-mediated apoptosis [131]. DCA has been taken through Phase 1 clinical trials given 
orally to patients with World Health Organization (WHO) grade III–IV gliomas or metasta-
ses from a primary cancer outside the central nervous system. It was feasible and well toler-
ated although genetic factors affecting tolerance were confirmed [132]. In Phase II clinical 
trials, DCA exhibited synergy when used with cisplatin and docetaxel leading to a sugges-
tion that it might be more effective and preferable for use in combination with other drugs 
[133]. It is noteworthy that these studies, together with the use of methyl pyruvate mentioned 
earlier, support a broad principle involving the reversal of the Warburg Effect as a plausible 
anti-cancer strategy.
5.3.2. Rotenone
Rotenone is a natural insecticide and an inhibitor of NADH dehydrogenase complex or com-
plex 1 of the mitochondrial electron transport chain (ETC). This results in the generation of 
reactive oxygen species and apoptosis [134, 135]. Because of its activity on ETC complex 1 
which is often altered in Parkinson’s disease, rotenone is sometimes used to create an animal 
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model of Parkinson’s disease [136]. It can thus be neurotoxic. Nevertheless, rotenone, given 
at subtoxic amounts, was used to reverse tumor necrosis factor-related apoptosis inducing 
Drug Mechanism of action Status Reference
Targeting glucose transporters
WZB117, STF-31 Inhibits GLUT1, thereby suppressing glucose 
transport
Preclinical [140, 141]
STF-31 Selectively inhibits Glut1 expression and 
completely induces apoptosis sin GLUT1 
expressing myeloma cells.
Preclinical [104]
ritonavir Has an off-target inhibitory effect on GLUT4. Approved for HIV [100]
Imatinib Inhibits Bcr-Abl tyrosine kinase; suppresses the 
activity of Hexokinase and G6PD
Approved for clinical 
use
[142]
Targeting glycolytic pathway
2-DG Inhibits HK, thereby suppressing glycolysis Clinical trials aborted [143, 144]
3-bromo- pyruvate An alkylating agent that inhibits HK Preclinical [97, 111, 145]
Lonidamine Suppresses glycolysis by inhibiting hexokinase 
II and OxPhos by dissociating HK2 from 
mitochondria
Clinical trials Phase 
II/III
[107, 108, 146]
FX11 Inhibits LDH-A Preclinical [125]
Oxamate Inhibits LDH-A Preclinical [127, 128]
TEPP-46 Activates PKM2 and suppresses the PPP Preclinical [118, 147]
Oxythiamine Inhibits transketolase thereby suppressing the 
PPP; inhibits pyruvate dehydrogenase
Preclinical [130]
Targeting OXPHOS
Dichloroacetate Inhibits the pyruvate dehydrogenase complex Phase II [131–133]
Pyruvate esters Boost OXPHOS Experimental [89, 113, 114]
Rotenone Inhibits complex 1 in OXPHOS Preclinical [135, 148]
Targeting glutamine pathway
L-γ-glutamyl-p-
nitroanilide
Inhibits SLC1A5 (also known as (ASCT2) Preclinical [138]
BCH inhibits glutamine/leucine exchange and mTOR 
activation
Preclinical [139]
Benzylserine inhibits glutamine transport by targeting both 
LAT1 and ASCT2
Preclinical [139]
BPTES inhibit glutaminase Preclinical [139]
CB-839 unknown Preclinical [139]
Compound 968 Probablt tarets by Rho GTPases Preclinical [139]
EGCG inhibits GDH Preclinical [139]
Table 2. Potential anti-cancer drugs targeting glucose metabolism.
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ligand (TRAIL) resistant non-small cell lung carcinoma (NSCLC) cells in a p53-dependent 
manner that was also related to generation of reactive oxygen species [137]. Although, rote-
none does not target glucose metabolism but rather the integral structure of the mitochon-
drion, it would affect glucose metabolism indirectly. It falls within a class of drugs that target 
the structural integrity of the mitochondrion, including resveratrol, Vitamin E analogs, arse-
nic trioxide, honokiol and betulinic acid [127].
5.4. Drugs targeting the glutamine pathway
Glutamine is a non-essential amino acid that can be produced from glucose. It is known that 
cancer cells have a propensity to consume large amounts of glutamine and undergo dra-
matic metabolic programming geared at production of anabolic precursors from glutamine. 
Glutamine, a mitochondrial substrate, enters the cell via high affinity glutamine transporters 
and is converted into glutamic acid and then into the tricarboxylic acid (TCA) cycle metabo-
lite, α-ketoglutarate [47]. A window for anti-cancer drug development is therefore open at the 
level of glucose uptake. The Na(+)-dependent neutral amino acid transporter type 2 (ASCT2) 
is encoded by the solute-linked carrier family A1 member 5 (SLC1A5) gene and inhibited by L-γ-
glutamyl-p-nitroanilide or GPNA via mTOR signaling [138]. New drugs targeting glutami-
nolysis have been reviewed by Jin et al. [139] and are listed in Table 2.
6. Conclusions
The metabolic reprogramming that occurs during carcinogenesis and also upon infections 
provides a window of opportunity for anti-cancer drug discovery and development. The 
molecular mechanisms that underlie this phenotype are being elucidated at a rapid pace fur-
ther helping the development of therapeutic strategies. However, there are still key ques-
tions to be addressed with regards to the Warburg Effect. Firstly, it is still to be ascertained 
whether this phenomenon is a cause or a consequence of carcinogenesis. Secondly, the role 
of the tumor suppressor p53 which intervenes at multiple points in the glucose metabolic 
pathway seems essential as demonstrated by the elegant work of the Feng group at Rutgers 
University who showed a gain-of-function phenotype in p53 which stimulates the Warburg 
Effect. However, it seems that this phenomenon can occur in a wild type p53 background. 
Altogether, glucose metabolism offers exciting opportunities for anti-cancer drug discovery 
and development.
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